Virtual Screening and Biological Characterization of Novel Histone Arginine Methyltransferase PRMT1 Inhibitors
Citations Over TimeTop 10% of 2008 papers
Abstract
Lysine and arginine methyltransferases participate in the posttranslational modification of histones and regulate key cellular functions. Protein arginine methyltransferase 1 (PRMT1) has been identified as an essential component of mixed lineage leukemia (MLL) oncogenic complexes, revealing its potential as a novel therapeutic target in human cancer. The first potent arginine methyltransferase inhibitors were recently discovered by random- and target-based screening approaches. Herein we report virtual and biological screening for novel inhibitors of PRMT1. Structure-based virtual screening (VS) of the Chembridge database composed of 328 000 molecules was performed with a combination of ligand- and target-based in silico approaches. Nine inhibitors were identified from the top-scored docking solutions; these were experimentally tested using human PRMT1 and an antibody-based assay with a time-resolved fluorescence readout. Among several aromatic amines, an aliphatic amine and an amide were also found to be active in the micromolar range.
Related Papers
- → The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells(2019)41 cited
- → The Where and the How of PRMT5(2015)27 cited
- → Characterization of the Drosophila protein arginine methyltransferases DART1 and DART4(2004)70 cited
- Modulation of the tumor suppressor p53 pathway by arginine methyltransferases(2008)
- → The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells.(2019)